New drug duo aims to wipe out stomach cancer before surgery
NCT ID NCT07315035
First seen Jan 08, 2026 · Last updated May 24, 2026 · Updated 21 times
Summary
This study tests whether adding an experimental immunotherapy drug (QL1706) to standard chemotherapy (SOX) before surgery can completely eliminate stomach cancer in adults with advanced but removable tumors. About 74 people aged 18-75 will be randomly assigned to get either the combination or chemo alone for 3-4 cycles, then undergo surgery. Researchers will compare how many patients have no cancer left in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.